Figure 6.

Effects of (A) free RAV, RAV–SEDDS (10 mg/mL) and (B) blank SEDDS (BL-SEDDS) and each SEDDS excipient tested separately on infection inhibition of T. cruzi (Y strain) amastigotes in H9c2 cells.

Notes: M: Miglyol 810N; Ep: Epikuron 170; L: Labrasol; and Et: ethanol were tested at two doses equivalent to ravuconazole IC₅₀ and IC₉₀, (0.1 nM and 0.5 nM, respectively) under our experimental conditions. *Indicates significant differences by Tukey’s multiple-comparisons test (P<0.05). IC₅₀ and IC₉₀, the concentration of drug needed to inhibit 50% or 90%, respectively, of parasite growth.

Abbreviations: RAV, ravuconazole; SEDDS, self-emulsifying drug delivery system; T. cruzi, Trypanosoma cruzi.